亚盛医药-B港股市值165.16亿港元，在化学制药行业中排名第9。主要指标见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 3月26日，头部创新药企业亚盛医药(NASDAQ：AAPG;HKEX：6855)发布2025年全年业绩。报告期 内，公司实现总收入5.74亿元人民币，商业化实现强劲增长。作为公司首款商业化产品，耐立克(奥雷 巴替尼)在2025年迎来医保落地后的首个完整销售年份，销售额实现显著增长，达到4.35亿元人民币， 同比大幅增长81%。公司第二款产品、中国首个上市的国产原创Bcl-2抑制剂利生妥(利沙托克拉)自2025 年7月获批后快速放量，截至报告期末的5个月内实现销售额7058万元人民币。公司现金流持续改善，货 币资金充沛，截至报告期末总货币资金约24.7亿元人民币。业绩增长由已上市的两大核心产品"双引 擎"高效驱动。 投行对该股关注度不高，90天内无投行对其给出评级。 ...

格隆汇3月26日｜今日，亚盛医药（NASDAQ：AAPG；HKEX：6855）公布2025年全年业绩。报告期 内，公司商业化实现强劲增长，内生增长动力显著。凭借由已上市产品耐立克与利生妥构成的"双引 擎"驱动，及在研产品管线的持续推进，公司在血液肿瘤领域构建起坚实的领导地位。 亚盛医药坚定践行以患者为中心的"全球创新"战略。2025年，亚盛医药的创新实力持续获得全球顶级学 术会议的高度认可，多项重要临床研究数据在国际舞台重磅发布，进一步巩固了公司在全球血液肿瘤领 域的领先地位与影响力。报告期内，公司多项注册III期临床研究快速推进，其中四项获美国FDA和欧洲 EMA许可。特别是利生妥治疗中高危MDS的全球注册III期研究（GLORA-4）是为目前国际上唯一正推 进中高危MDS注册III期临床的Bcl-2抑制剂。此外，公司其他产品管线也齐头并进，共同构建了协同发 展的创新矩阵，为长期增长注入新动能。基于PROTAC技术平台的新型BTK降解剂APG-3288的新药临 床申请已于2026年年初获美国FDA和中国CDE许可，创新管线再添新翼。 报告期内，公司首款商业化产品、中国首个获批上市的第三代BCR-ABL抑制剂 ...

Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales of Olverembatinib increased 81% year-over-year to US$62.2 million (RMB435.3 million) Sales of Lisaftoclax since launch during last five months of 2025 were US$10.1 million (RMB 70.6 million)Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMAChinese (Mandarin) investor event with simultaneous conference call and webcast at 10:0 ...

ROCKVILLE, Md. and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that four abstracts highlighting the latest preclinical results from its pipeline programs have been selected for poster presentations at the American Association of ...

Core Viewpoint - Ascentage Pharma Group International will release its full year 2025 unaudited results and provide business updates on March 25, 2026, at 7:00 pm EDT [1] Group 1: Upcoming Events - Analysts and investors are invited to join an investor webcast with Q&A conducted by the company's management team, scheduled for March 25, 2026, at 10:00 pm EDT [2] - An English language investor webcast will be held on March 26, 2026, at 8:00 am EDT, with a replay available on the company's website [3] Group 2: Company Overview - Ascentage Pharma is a global, commercial stage, integrated biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for unmet medical needs in cancer [4] - The company has developed a rich pipeline of innovative drug products, including inhibitors targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [4] Group 3: Approved Products - The first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor for treating chronic myeloid leukemia (CML) with specific mutations and is included in China's National Reimbursement Drug List [5] - The second approved product, Lisaftoclax, is a Bcl-2 inhibitor for various hematologic malignancies and has been approved for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have received prior systemic therapy [6] Group 4: Research and Development - Ascentage Pharma has established a portfolio of global intellectual property rights and formed partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer [7]

Core Viewpoint - Ascentage Pharma Group International is actively participating in investor conferences to enhance its visibility and engagement with investors, showcasing its innovative therapies for cancer treatment [1][8]. Company Overview - Ascentage Pharma is a global, commercial stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies to meet unmet medical needs in cancer [3]. - The company has developed a robust pipeline of innovative drug products, including inhibitors targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [3]. Key Products - The lead asset, Olverembatinib, is the first third-generation BCR-ABL1 inhibitor approved in China for treating chronic myeloid leukemia (CML) with T315I mutations and is included in the China National Reimbursement Drug List [4]. - The second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for treating various hematologic malignancies and is currently being commercialized in China [5]. Clinical Trials - Ascentage Pharma is conducting a global registrational Phase III trial, POLARIS-2, for Olverembatinib in CML, along with additional Phase III trials for newly diagnosed Ph+ acute lymphoblastic leukemia (ALL) and SDH-deficient gastrointestinal stromal tumors (GIST) [4]. - The company is also running four global registrational Phase III trials for Lisaftoclax, including studies in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and acute myeloid leukemia (AML) [5]. Partnerships and Collaborations - Ascentage Pharma has established a portfolio of global intellectual property rights and formed partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer [6].

Company Overview - Ascentage is a public company dual listed on NASDAQ and Hong Kong Stock Exchange with close to 800 employees [2] - The company is in a commercial stage in China with 2 novel products for oncology indications in hematology and is experiencing rapid growth [2] Product Pipeline - Ascentage has a pipeline of 7 disclosed compounds, including the 2 products mentioned, each with novel, best-in-class potential targeting major markets in hematology [3] - The company possesses an internal discovery engine to support its product development [3] Global Strategy - The employee distribution is predominantly in China, focusing on discovery, innovation, clinical trial execution, and sales, while over 100 employees are based in the U.S. [4] - The U.S. is identified as the global market hub for Ascentage, with 4 ongoing U.S. registration studies, marking the next chapter in the company's global commercial expansion [4]

Company Overview - Ascentage Pharma Group International (NASDAQ:AAPG) is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancers and age-related diseases, founded in 2009 and headquartered in Suzhou, China [4]. Investment Potential - Rodman & Renshaw initiated coverage of Ascentage Pharma with a Buy rating and a price target of $48, highlighting the company's differentiated hematology-focused pipeline and progress in clinical-stage assets [1]. - The firm's analysis emphasizes Ascentage's innovative approach to addressing drug resistance in blood cancers as a significant driver for potential upside as its next-generation programs advance [1]. Clinical Developments - On February 5, 2026, Ascentage announced that its next-generation BTK-targeted protein degrader, APG-3288, received investigational new drug clearance from both China's Center for Drug Evaluation and the U.S. FDA [3]. - The company plans to initiate a multicenter Phase I trial for APG-3288 in patients with relapsed or refractory hematologic malignancies, utilizing PROTAC technology to degrade both wild-type and mutant BTK, which may overcome resistance seen with existing therapies [3]. - The dual IND clearances are seen as a means to significantly de-risk the program and support faster global clinical development [3].

Core Viewpoint - Ascentage Pharma Group International is actively participating in the Guggenheim Emerging Outlook: Biotech Summit 2026, highlighting its commitment to addressing unmet medical needs in cancer through innovative therapies [1][2]. Company Overview - Ascentage Pharma is a global, commercial stage, integrated biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for cancer [3]. - The company has developed a rich pipeline of innovative drug products, including inhibitors targeting key proteins in the apoptotic pathway and next-generation kinase inhibitors [3]. Key Products - The lead asset, Olverembatinib, is the first third-generation BCR-ABL1 inhibitor approved in China for treating chronic myeloid leukemia (CML) with T315I mutations and is included in the China National Reimbursement Drug List [4]. - Olverembatinib is currently undergoing a global registrational Phase III trial (POLARIS-2) for CML and additional trials for newly diagnosed Ph+ acute lymphoblastic leukemia (ALL) and SDH-deficient gastrointestinal stromal tumors (GIST) [4]. - The second approved product, Lisaftoclax, is a novel Bcl-2 inhibitor for hematologic malignancies, currently being commercialized in China for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [5]. - Lisaftoclax is involved in four global registrational Phase III trials, including studies in combination with BTK inhibitors and in newly diagnosed patients with various hematologic conditions [5]. Research and Development - Ascentage Pharma has established a robust R&D capability and holds a portfolio of global intellectual property rights [6]. - The company has formed partnerships with leading biotechnology and pharmaceutical companies, including Takeda, AstraZeneca, Merck, and Pfizer, as well as collaborations with prominent research institutions [6].

Core Viewpoint - Ascentage Pharma has received investigational new drug (IND) application clearance for its novel BTK-targeted protein degrader, APG-3288, from the China Center for Drug Evaluation (CDE), following similar clearance from the U.S. FDA, marking a significant milestone in its clinical development for patients with relapsed/refractory hematologic malignancies [1][6]. Group 1: Drug Development and Clinical Trials - APG-3288 is set to enter a multicenter, open-label Phase I study to evaluate its safety, tolerability, pharmacokinetic profile, and preliminary efficacy in patients with relapsed/refractory hematologic malignancies [2]. - The IND clearance for APG-3288 enhances Ascentage Pharma's pipeline in hematologic malignancies, complementing existing products like Olverembatinib and Lisaftoclax, which have already been approved in China [5]. Group 2: Mechanism of Action and Innovation - APG-3288 utilizes Ascentage Pharma's proprietary PROTAC technology to induce the degradation of BTK, overcoming resistance associated with conventional BTK inhibitors by blocking the BCR-BTK signaling axis at its source [4]. - The drug is designed to provide a novel therapeutic strategy by inducing rapid and sustained degradation of both wild-type BTK and multiple BTK mutants, addressing the urgent clinical need for new treatment options in B-cell malignancies [3][4]. Group 3: Company Background and Strategy - Ascentage Pharma is a global biopharmaceutical company focused on developing innovative therapies for cancer, with a strong presence in hematologic malignancies and a diverse pipeline of drug candidates [8]. - The company has established partnerships with leading biotechnology and pharmaceutical firms, enhancing its research and development capabilities and expanding its global reach [11].